Validation of a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer

被引:1
作者
Van der Vorst, Aline [1 ]
Kindts, Isabelle [2 ]
Laenen, Annouschka [3 ]
Neven, Patrick [4 ]
Janssen, Hilde [1 ]
Weltens, Caroline [1 ]
机构
[1] UZ Leuven, Dept Radiat Oncol, Herestr 49, B-3000 Leuven, Belgium
[2] AZ Groeninge, Dept Radiat Oncol, President Kennedylaan 4, B-8500 Kortrijk, Belgium
[3] UZ Leuven, Dept Biostat & Stat Bioinformat, Herestr 49, B-3000 Leuven, Belgium
[4] UZ Leuven, Dept Gynaecol, Herestr 49, B-3000 Leuven, Belgium
关键词
Breast cancer; Radiotherapy; Mastectomy; Locoregional recurrence; Prognostic scoring system; RADIOTHERAPY; AXILLARY; MASTECTOMY; WOMEN; RISK; TUMOR; PREDICTIONS; DIAGNOSIS; MORTALITY; SURVIVAL;
D O I
10.1016/j.breast.2022.04.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To date, it remains unclear which patients with breast cancer (BC) benefit from post-mastectomy radiotherapy (PMRT). Cheng et al. developed and validated a scoring system based on 4 prognostic factors for locoregional recurrence (LRR) to identify patients in need for PMRT. These factors include age, estrogen receptor status, lymphovascular status and number of affected axillary lymph nodes. Purpose: To validate the scoring system for LRR in BC developed by Cheng et al. by using an independent BC database. Methods and materials: We retrospectively identified 1989 BC cases, treated with mastectomy (ME) with or without PMRT at the University Hospitals Leuven between 2000 and 2007. The primary endpoint was 5-year locoregional control rate with and without PMRT, according to the LRR score. Results: Median follow-up time was 11.4 years. After excluding patients with missing variables 1103 patients were classified using the LRR scoring system: 688 (62.38%) patients were at low risk of recurrence (LRR score 0-1), 335 (30.37%) patients were at intermediate risk of recurrence (LRR score 2-3) and 80 (7.25%) patients were at high risk of recurrence (LRR score >= 4). 5-year locoregional control rates with and without PMRT were 99.20% versus 99.21% (p = 0.43) in the low-risk group; 98.24% versus 85.74% (p < 0.0001) in the intermediate-risk group and 96.87% versus 85.71% (p = 0.10) in the high-risk group respectively. Conclusion: Our validation of the LRR scoring system suggests it can be used to point out patients that would benefit from PMRT. We recommend further validation of this scoring system by other independent institutions-before application in clinical practice.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 26 条
  • [21] T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy
    Wang, Xueying
    Xu, Yingying
    Guo, Shanshan
    Zhang, Jiaxin
    Abe, Masanobu
    Tan, Haosheng
    Wang, Shaojun
    Chen, Ping
    Zong, Liang
    [J]. ONCOLOGY LETTERS, 2020, 19 (01) : 735 - 744
  • [22] Evolving rationale for post-mastectomy radiation
    Wilson, J. Frank
    Currey, Adam D.
    [J]. BREAST JOURNAL, 2018, 24 (01) : 5 - 6
  • [23] Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation
    Woodward, WA
    Strom, EA
    Tucker, SL
    Katz, A
    McNeese, MD
    Perkins, GH
    Buzdar, AU
    Hortobagyi, GN
    Hunt, KK
    Sahin, A
    Meric, F
    Sneige, N
    Buchholz, TA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (02): : 336 - 344
  • [24] Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial
    Zeidan, Youssef H.
    Habib, Joyce G.
    Ameye, Lieveke
    Paesmans, Marianne
    de Azambuja, Evandro
    Gelber, Richard D.
    Campbell, Ian
    Nordenskjold, Bo
    Gutierez, Jorge
    Anderson, Michael
    Lluch, Ana
    Gnant, Michael
    Goldhirsch, Aron
    Di Leo, Angelo
    Joseph, David J.
    Crown, John
    Piccart-Gebhart, Martine
    Francis, Prudence A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : 316 - 324
  • [25] Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients
    Zhao, Jia-ming
    An, Qi
    Sun, Chao-nan
    Li, Yu-bing
    Qin, Zi-lan
    Guo, Hong
    Zeng, Xue
    Zhang, Yao-tian
    Wei, Lin-lin
    Han, Ning
    Sun, Shi-chen
    Zhang, Na
    [J]. BREAST CANCER, 2021, 28 (02) : 298 - 306
  • [26] Why validation of prognostic models matters?
    Zwanenburg, Alex
    Loeck, Steffen
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 127 (03) : 370 - 373